Aankondiging • May 12
Sangamo Therapeutics, Inc. to Report Q1, 2026 Results on May 14, 2026 Sangamo Therapeutics, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 14, 2026 Aankondiging • May 06
Sangamo Therapeutics, Inc.(OTCPK:SGMO) dropped from NASDAQ Composite Index Sangamo Therapeutics, Inc. has been dropped from the NASDAQ Composite Index. Major Estimate Revision • Apr 07
Consensus revenue estimates increase by 22% The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$55.4m to US$67.6m. Forecast losses expected to reduce from -US$0.245 to -US$0.153 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$3.75. Share price rose 3.7% to US$0.26 over the past week. Aankondiging • Apr 01
Sangamo Therapeutics, Inc. Reports Unaudited consolidated Impairment Charges for the Fourth Quarter Ended December 31, 2025 Sangamo Therapeutics, Inc. reported Unaudited consolidated impairment charges for the fourth quarter ended December 31, 2025. For the period, the company reported impairment of long-lived assets of $13,235,000. Reported Earnings • Mar 31
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: US$0.44 loss per share. Revenue: US$39.6m (down 32% from FY 2024). Net loss: US$122.9m (loss widened 26% from FY 2024). Revenue missed analyst estimates by 40%. Earnings per share (EPS) also missed analyst estimates by 42%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Aankondiging • Mar 20
Sangamo Therapeutics, Inc. to Report Q4, 2025 Results on Mar 30, 2026 Sangamo Therapeutics, Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 30, 2026 Aankondiging • Mar 10
Sangamo Therapeutics, Inc. Advances Rolling Submission Of BLA To U.S. FDA For ST-920 In Fabry Disease Sangamo Therapeutics, Inc. announced advancement of the rolling submission of a BLA to the FDA seeking accelerated approval of isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. Following initiation of the rolling submission in December 2025, Sangamo has now submitted the preclinical and clinical modules to the FDA for review. Rolling submission allows for completed modules of the BLA to be submitted and reviewed by the FDA on an ongoing basis rather than waiting for the entire BLA to be submitted at once. In addition, the antibody assay companion diagnostic, which is designed to screen patients for eligibility with isaralgagene civaparvovec, has been submitted to, and accepted by, the FDA’s Center for Devices and Radiological Health (CDRH) seeking Premarket Approval (PMA). The STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which the FDA has agreed will serve as endpoint to support accelerated approval. These data were presented via four platform presentations and in poster presentations at the recent 22nd Annual WORLDSymposium™. These data are available on Sangamo’s website on the Presentations page. The Phase 1/2 STAAR study is a global open-label, single-dose, dose-ranging, multicenter clinical study designed to evaluate isaralgagene civaparvovec, or ST-920, a gene therapy product candidate in patients with Fabry disease. Isaralgagene civaparvovec requires a one-time infusion without preconditioning. Isaralgagene civaparvovec has been granted Orphan Drug, Fast Track and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from U.K. Medicines and Healthcare products Regulatory Agency. Fabry disease is a lysosomal storage disorder caused by mutations in the galactosidase alpha gene (GLA), which leads to deficient alpha-galactosidase A (a-Gal A) enzyme activity, which is necessary for metabolizing globotriaosylceramide (Gb3). The buildup of Gb3 in the cells can cause serious damage to vital organs, including the kidney, heart, nerves, eyes, gut and skin. Symptoms of Fabry disease can include decreased or absent sweat production, heat intolerance, angiokeratoma (skin blemishes), vision problems, kidney disease, heart failure, gastrointestinal disturbance, mood disorders, neuropathic pain and tingling in the extremities. Aankondiging • Feb 04
Sangamo Therapeutics, Inc. Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium 2026 Sangamo Therapeutics, Inc. announced detailed data from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. These data will be presented via four platform presentations and in poster presentations at the 22nd Annual WORLDSymposium taking place in San Diego, CA, February 2-6, 2026.Sangamo believes that the totality of data from the registrational STAAR study demonstrates the potential of isaralgagene civaparvovec as a one-time, well-tolerated and durable gene therapy treatment option for Fabry disease to provide meaningful, multi-organ clinical benefits that could fundamentally shift the Fabry treatment paradigm. As of the April 10, 2025 data cut-off date, a positive mean annualized eGFR slope of 1.965 mL/min/1.73m/year (95% confidence interval (CI): -0.153, 4.083) at 52-weeks was observed across all 32 dosed patients, indicating an improvement in renal function. Furthermore, a mean annualized eGFR slope of 1.747 mL/min/1.73m/year (95% CI: -0.106, 3.601) was observed for the 19 patients who had achieved 104-weeks of follow-up. Stable cardiac function was observed over one year, including consistent cardiac structural stability across clinical and demographic subgroups. Durability of effect was demonstrated with elevated expression of alpha-galactosidase A (a-Gal A) activity maintained for up to 4.5 years for the longest treated patient, alongside statistically significant Quality of Life improvements and other clinical benefits. Isaralgagene civaparvovec demonstrated a favorable safety and tolerability profile in the study, without the requirement for preconditioning. The Phase 1/2 STAAR Study is complete, and 32 patients have successfully rolled into the long-term follow-up study. The FDA has provided a clear regulatory pathway to Accelerated Approval for isaralgagene Civaparvovec, agree that data from the ongoing Phase 1/2 STAAR trial can serve as the primary basis for approval under the Accelerated Approval Program, using mean annualized eGFR slope at 52 weeks as an intermediate clinical endpoint. In December 2025, Sangamo initiated a rolling submission of a BLA to the FDA seeking approval of isaralgagene civAParvovec under an Accelerated Approval pathway. Aankondiging • Feb 03
Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24.822129 million. Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24.822129 million.
Security Name: common Stock
Security Type: Common Stock
Securities Offered: 35,190,292
Price\Range: $0.4719
Discount Per Security: $0.0283
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 17,787,033
Price\Range: $0.4619
Discount Per Security: $0.0277 New Risk • Jan 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$76m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Aankondiging • Dec 18
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease Sangamo Therapeutics, Inc. has initiated a rolling submission of a BLA to the FDA seeking accelerated approval of isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. Rolling submission allows for completed modules of the BLA to be submitted and reviewed by the FDA on an ongoing basis rather than waiting for the entire BLA to be submitted at once. Furthermore, the STAAR study demonstrated a positive mean annualized eGFR slope at 52-we weeks across all dosed patients in the study, which the FDA has agreed will serve as endpoint to support accelerated approval. Isaralgagene civapARvovec has been granted Orphan Drug, Fast Track and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from U.K. Medicines and Healthcare products Regulatory Agency. Sangamo expects to complete submission of the BLA to the FDA under the accelerated approval pathway in the second quarter of 2026. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. These forward-looking statements include, without limitation, statements relating to: the safety and efficacy and therapeutic potential of isaralgagene Civaparvovec, including the potential for it to be a one-time, durable treatment option for Fabry disease to provide meaningful, multi-organ clinical benefits above current standards of care; the potential for isaralgagene civapearvovec to qualify for the FDA's accelerated approval program, including the adequacy of data generated in the Phase 1/2 STAAR study to support any such approval; expectations regarding the availability of additional data to support a potential BLA submission for isaralgagene Civapearvovec, and the timing of such submission; and other statements that are not historical fact. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to Sangamo's lack of capital resources to obtain regulatory approval for and commercialize its product candidates in a timely manner or at all, including the ability to secure a commercialization partner for ST-920; the uncertain timing and unpredictable nature of clinical trial results, including the risk that preliminary or topline data is not indicative of final results, that the therapeutic effects observed in the latest clinical data from the Phase 1/2 STAar study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civilaparvovec,including that the 52-week data from the Phase 1/2 STAAR study will not support a BLA submission and/or that the 104-week data from such study will not verify the clinical benefit of isaralgagene civicaparvovec or support FDA approval, and that the patients withdrawn from ERT will remain off ERT; All forward-looking statements about Sangamo's future plans and expectations, including Sangamo's development plans for its product candidates, are subject to Sangamo's ability to secure adequate additional funding. There can be no assurance that Sangamo and its current or potential future partners will be able to develop a clinical trial data from the Phase 1/1/2 STAAR study will not support the clinical benefit of isaralagene civaparvovovec or support FDA approval. Breakeven Date Change • Dec 07
Forecast to breakeven in 2027 The 4 analysts covering Sangamo Therapeutics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 11% per year to 2026. The company is expected to make a profit of US$15.7m in 2027. Average annual earnings growth of 72% is required to achieve expected profit on schedule. Aankondiging • Dec 02
Sangamo Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy Sangamo Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain. Fast Track Designation aims to facilitate the development and expedite the review of new therapeutics that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Companies granted this designation are given the opportunity for more frequent interactions with the FDA. These clinical programs may also be eligible to apply for Accelerated Approval and Priority Review if relevant criteria are met. ST-503 is currently being evaluated in the Phase 1/2 STAND study, where patient recruitment and enrollment are in progress. In September 2025, Sangamo presented updated nonclinical data highlighting the pharmacology and safety of ST-503 in chronic neuropathic pain at the 9th International Congress on Neuropathic Pain. The data demonstrated the durability, potency and selectivity of ST-503 in nonhuman primates, alongside a favorable safety profile, supporting its development for the treatment of chronic neuropathic pain. A copy of the presentation is available in the Presentations section of the Sangamo website. Ant antidepressantsants, anticonvulsants, opioids and topical therapies are potential treatment options, although no long-lasting or curative therapies are currently available for SFN patients, leading to a high unmet medical need for this patient population. Aankondiging • Nov 22
Sangamo Therapeutics, Inc. Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease Sangamo Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo's request for a rolling submission and review of the Biologics License Application (BLA) for isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. This acceptance follows Sangamo's meeting with the FDA in October 2025 to discuss the proposed efficacy and safety data package for isaralgagene Civaparvovec where, in the meeting minutes, among other things, the FDA reiterated its October 2024 agreement to use eGFR slope as an endpoint to support an accelerated approval pathway. Sangamo presented detailed clinical data from the registrational Phase 1/2 STAAR study at the International Congress of Inborn Errors of Metabolism 2025 (ICIEM2025) in September, which demonstrated the potential for isaralgagene civilaparvovec as a one-time, durable treatment of underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care. Furthermore, the STAAR study demonstrated a positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-we weeks across allosed patients in the study, which the FDA has agreed will serve as the primary basis of approval. Isaralgagene civapARvovec has been granted Orphan Drug, Fast Track and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from U.K. Medicines and Healthcare products Regulatory Agency. Sangamo plans to initiate rolling submission of the BLA to the FDA under the accelerated approval pathway later in the fourth quarter of 2025. These forward-looking statements include, without limitation, statements relating to: the safety and efficacy and therapeutic potential of isaralgagene civAParvovec, including the potential for isaralgAGene civaparvoveC, including that the 52-week data from the Phase 1/2 STAAR trial will not support a BLA submission and/or that the 104-week data from such study will not verify the clinical benefit of isaralgagene Civapec or support FDA approval, and that the patients withdrawn from ERT will remain off ERT; All forward-looking statements about Sangamo's future plans and expectations, including Sangamo's development plans for its product candidates, are subject to Sangamo's ability to secure adequate additional funding. There can be no assurance that Sangamo and its current or potential future partners. Major Estimate Revision • Nov 14
Consensus revenue estimates fall by 37% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$72.3m to US$45.6m. Forecast losses increased from -US$0.291 to -US$0.397 per share. Biotechs industry in the US expected to see average net income decline 9.7% next year. Consensus price target of US$3.25 unchanged from last update. Share price fell 2.5% to US$0.45 over the past week. Price Target Changed • Nov 07
Price target decreased by 21% to US$3.25 Down from US$4.10, the current price target is an average from 5 analysts. New target price is 589% above last closing price of US$0.47. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$0.42 next year compared to a net loss per share of US$0.49 last year. Reported Earnings • Nov 06
Third quarter 2025 earnings released: US$0.12 loss per share (vs US$0.045 profit in 3Q 2024) Third quarter 2025 results: US$0.12 loss per share (down from US$0.045 profit in 3Q 2024). Revenue: US$581.0k (down 99% from 3Q 2024). Net loss: US$34.9m (down 472% from profit in 3Q 2024). Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. Aankondiging • Oct 31
Sangamo Therapeutics, Inc. to Report Q3, 2025 Results on Nov 06, 2025 Sangamo Therapeutics, Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 06, 2025 Aankondiging • Oct 30
Nasdaq Grants 180 Day Extension to Sangamo Therapeutics, Inc. to Regain Compliance On October 29, 2025, Sangamo Therapeutics, Inc. (the Company") received a letter (the Extension Notice") from The Nasdaq Stock Market LLC (Nasdaq") advising that the Company has been granted a 180-day extension, or until April 27, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"), in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time prior to April 27, 2026, the bid price of the Company's common stock, par value $0.01 per share (Common Stock"), closes at $1.00 per share or more for a minimum of 10 consecutive trading days, the Company will regain compliance with the Minimum Bid Price Requirement. The Extension Notice has no immediate effect on the listing of the Common Stock on The Nasdaq Capital Market and does not affect the Company's reporting requirements with the Securities and Exchange Commission (SEC"). As previously disclosed on the Current Report on Form 8-K filed with the SEC on May 5, 2025, the Company received a letter on April 30, 2025 from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Common Stock, for the preceding 30 consecutive business days, the Company was not in compliance with the Minimum Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until October 27, 2025, to regain compliance with the Minimum Bid Price Requirement. The Company intends to cure the Minimum Bid Price Requirement by April 27, 2026, however if the Company does not regain compliance with the Minimum Bid Price Requirement during this period, the Company expects that Nasdaq will provide written notification to the Company that its Common Stock will be delisted. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq listing rules. However, there can be no assurance that, if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the additional 180-day compliance period or maintain compliance with any other Nasdaq listing requirement. Aankondiging • Sep 04
Sangamo Therapeutics, Inc. Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 Sangamo Therapeutics, Inc. announced detailed data from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. These data were presented at the International Congress of Inborn Errors of Metabolism 2025 (ICIEM2025) in Kyoto, Japan, on September 4, 2025, in a poster presentation. Updated Phase 1/2 STAAR Study Results (as of April 10, 2025 cut-off date) Efficacy (32 dosed patients followed at least 12 months); A positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year (95% confidence interval (CI): -0.153, 4.083) at 52-we weeks was observed across all 32 dosed patients. Isaralgagene civapARvovec has been granted Orphan Drug, Fast Track and RMAT designations from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from U.K. Medicines and Healthcare products Regulatory Agency. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to Sangamo's lack of capital resources and need for substantial additional funding to execute its operating plan and to continue to operate as a going concern, including the risk that Sangamo will be unable to obtain substantial additional funding on acceptable terms or at all or collaboration partners necessary to advance its preclinical and clinical programs, in particular for its Fabry disease program and to otherwise operate as a going concern, in which case Sangamo may be required to cease operations entirely, liquidate all or a portion of its assets and/or seek protection under the U.S. Bankruptcy Code; the uncertain timing and unpredictable nature of clinical trial results, including the risk that the therapeutic effects observed in the latest clinical data from the Phase 1/2 STAAR trial will not validate the safety and efficacy of isaralgagene civapearvovec, including that the 104-week data from such study will not verify the clinical benefit of isaralgagene Civaparvovec or support FDA approval, and that the patients withdrawn from ERT will remain off ERT; the effects of macroeconomic factors or financial challenges, including as a result of the ongoing overseas conflicts, tariffs, geopolitical instability, inflation and fluctuations in interest rates, on the global business environment, healthcare systems and business and operations of Sangamo and its collaborators; the research and development process; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any regulatory trial of Sangamo's product candidates; the potential for technological developments that obviate technologies used by Sangamo; All forward-looking statements about Sangamo's future plans and expectations, including Sangamo's development plans for its product candidates, are subject to Sangamo's development plans for the treatment of adults withFabry disease. New Risk • Aug 11
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 45% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$36m free cash flow). Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$1.6m net loss in 3 years). Share price has been volatile over the past 3 months (16% average weekly change). Reported Earnings • Aug 10
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: US$0.078 loss per share (improved from US$0.17 loss in 2Q 2024). Revenue: US$18.3m (up US$18.0m from 2Q 2024). Net loss: US$20.0m (loss narrowed 43% from 2Q 2024). Revenue missed analyst estimates by 42%. Earnings per share (EPS) also missed analyst estimates by 100%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings. Aankondiging • Aug 01
Sangamo Therapeutics, Inc. to Report Q2, 2025 Results on Aug 07, 2025 Sangamo Therapeutics, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025 New Risk • May 15
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$98.4m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$68m net loss in 3 years). Market cap is less than US$100m (US$98.4m market cap). Major Estimate Revision • May 14
Consensus revenue estimates fall by 54% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$62.2m to US$28.7m. Forecast losses increased from -US$0.274 to -US$0.44 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$5.00 to US$4.10. Share price fell 33% to US$0.44 over the past week. New Risk • May 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$69m net loss in 3 years). Price Target Changed • May 13
Price target decreased by 21% to US$4.10 Down from US$5.17, the current price target is an average from 5 analysts. New target price is 791% above last closing price of US$0.46. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$0.42 next year compared to a net loss per share of US$0.49 last year. Aankondiging • May 13
Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $22.972713 million. Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $22.972713 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 12,235,000
Price\Range: $0.5
Discount Per Security: $0.03
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 34,398,393
Price\Range: $0.49
Discount Per Security: $0.0294 Aankondiging • May 06
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease Sangamo Therapeutics announced that all dosed patients have passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway for ST-920. Preliminary analysis of clinical data collected as of this 52-week milestone date across all 32 dosed patients indicates that the mean eGFR slope continued to remain positive, following the last clinical update at the WORLDSymposium in February 2025, with a data cutoff date of September 12, 2024. Furthermore, in April 2025, Sangamo held a productive Type B meeting with the FDA, providing Sangamo with a clear CMC pathway to a planned BLA submission in the first quarter of 2026, including clarity on plans for process validation, path to commercial specifications and the commercial launch manufacturing site. Aankondiging • May 01
Sangamo Therapeutics, Inc., Annual General Meeting, Jun 12, 2025 Sangamo Therapeutics, Inc., Annual General Meeting, Jun 12, 2025. Location: meetnow.global/murlfcm, United States Aankondiging • Apr 29
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) Sangamo Therapeutics, Inc. announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted nine Sangamo abstracts for presentation at the 28th ASGCT Annual Meeting being held May 13-17, 2025, in-person in New Orleans, LA and in a virtual format. Presentations will highlight the progression of Sangamo’s neurology pipeline, including advances in zinc finger epigenetic regulation, the latest innovations in capsid delivery engineering, and developments in modular integrase technology. Data presentations at the ASGCT Annual Meeting include three oral presentations that detail Sangamo’s advances in the application of zinc finger repressors (ZFRs) as a novel class of epigenetic regulation for neurological disease targets. Two presentations – including one taking place in the Presidential Symposium – showcase how Sangamo is combining its ZFR targeting the prion gene with STAC-BBB, its intravenously administered neurotropic capsid, for the treatment of prion disease, a fatal and incurable neurodegenerative disease. These presentations describe the profound survival benefits of the treatment in disease mouse models, and the sustained, brain-wide suppression of prion protein expression in both mouse and nonhuman primate models, supporting its potential as a one-time therapeutic approach for prion disease. The third presentation focuses on the advancement of ST-503, a ZFR targeting the gene encoding Nav1.7, for the treatment of intractable, chronic neuropathic pain following intrathecal delivery. Additional poster presentations at the ASGCT Annual Meeting will showcase advances in novel adeno-associated virus (AAV) capsid engineering and manufacturing for central nervous system (CNS) delivery. Topics range from second-generation STAC-BBB variants and receptor-targeted AAVs, to innovations in manufacturing and quality control, including strategies to enhance yield, purity, and stability, and improve analytical assessment of AAV products. Sangamo will also present updated data from its protein-guided MINT platform as an approach to enable engineering of large gene-sized pieces of DNA. Collectively, these abstracts highlight the versatility, durability, and translational potential of ZFR-based gene regulation across diverse neurological applications. New Risk • Apr 07
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$67m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$67m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$71m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Reported Earnings • Mar 18
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: US$0.49 loss per share (improved from US$1.48 loss in FY 2023). Revenue: US$57.8m (down 67% from FY 2023). Net loss: US$97.9m (loss narrowed 62% from FY 2023). Products in clinical trials Phase I: 1 Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) also missed analyst estimates by 4.9%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Aankondiging • Mar 07
Sangamo Therapeutics, Inc. to Report Q4, 2024 Results on Mar 17, 2025 Sangamo Therapeutics, Inc. announced that they will report Q4, 2024 results After-Market on Mar 17, 2025 Aankondiging • Feb 06
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile Sangamo Therapeutics, Inc. announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. Updated Phase 1/2 STAAR Study Results (as of the September 12, 2024 cut-off date) Safety (all dosed patients): Isaralgagene civapARvovec continued to be generally well-tolerated, with the majority of adverse events being grade 1-2 in nature. Enrollment and dosing are complete in the Phase 1/2 STAar study. In October 2024, Sangamo announced that the FDA had provided a clear regulatory pathway to Accelerated Approval for isaralgagene civAParvovec using data from ongoing Phase 1/2 STAAR trial study, avoiding the requirement for an additional registrational study and accelerating estimated time to potential approval by approximately three years. The FDA agreed in a Type B interaction that data from the ongoing Phase 1/2 STA AR study can serve as the primary basis for approval under the Accelerated Approval Program, using eGFR slope at 52 weeks across all patients as an intermediate clinical endpoint. The 52-week eGFR slope data from all enrolled patients in the Phase 1/2STAR study will be available in the first half of 2025. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including the central nervous system. These forward-looking statements include, without limitation, statements relating to: the safety and efficacy and therapeutic potential of isaralgagene Civaparvovec, including the potential for it to be a one-time, durable treatment option for Fabry disease that can improve patient outcomes; the presentation of clinical data from the phase 1/2 STAAR study; the potential for isaralgagene CivAParvovec to qualify for the FDA's Accelerated Approval program, including the adequacy of data generated in the Phase 1/2 ST-920 study to support any such approval; expectations concerning the availability of additional data to support a potential BLA submission for isaralgagene civicaparvovec, and the timing of such submission; the potential to accelerate the expected timeline to approval of isaralgagene civapearvovec; Sangamo's plans to advance discussions with the FDA and the European Medicines Agency; Factors that could cause actual results to difference include, but are not limited to, risks and uncertainties related to Sangamo's lack of capital resources to obtain regulatory approval for and commercialize its product candidates in a timely manner or at all, including the ability to secure a collaboration partner for ST-920; the uncertain timing and unpredictable nature of clinical trial results, including the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene citizensaparvovec, a fully owned gene therapy product candidate for ST-920, a wholly owned gene therapy product candidate for Fabry disease. Aankondiging • Nov 20
Sangamo Therapeutics, Inc. Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain Sangamo Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for its ST-503 program, an investigational epigenetic regulator for the treatment of intractable pain due to idiopathic small fiber neuropathy (iSFN), a type of chronic neuropathic pain. Neuropathic pain can be caused by a broad array of pathologies impacting the central or peripheral nervous systems, such as surgical trauma, spinal cord injury, nerve compression, neurological and infectious diseases, or metabolic and hereditary syndromes. ST-503 is not intended for sporadic or acute pain, but for chronic, intractable pain that completely dominates and often destroys the lives of patients over many years. The Phase 1/2 study will assess the safety and efficacy of ST-503 in addressing iSFN, a peripheral neuropathy that results in highly debilitating symptoms of burning, prickling, stabbing or “lightning-like” pain. iSFN has an estimated prevalence of at least 43,000 patients in the U.S., and more broadly, peripheral neuropathies are estimated to affect nearly 40 million Americans. Antidepressants, anticonvulsants, opioids and topical therapies are potential treatment options, although no long-lasting or curative therapies are currently available for iSFN patients, leading to a high unmet medical need for this patient population. A significant body of evidence implicates sodium channels in mediating the pathophysiology of neuropathic pain. ST-503 uses an adeno-associated virus (AAV) vector carrying an engineered zinc finger repressor (ZFR) to specifically target the human gene, SCN9A, that encodes the Nav1.7 sodium channel and is critical for pain signaling. Developing small molecules that specifically target Nav1.7 is challenging due to the high structural similarities between different sodium channels, making it difficult to achieve selectivity and avoid off-target effects. By directly targeting the SCN9A gene, ST-503 was shown to selectively reduce the expression of Nav1.7 sodium channels in sensory neurons in animal models and significantly reduce pain hypersensitivity, following a single intrathecal administration of ST-503. Sangamo’s preclinical research has shown ST-503 to be well tolerated in nonhuman primates, with substantial Nav1.7 reduction observed with no off-target effects, demonstrating the promise of ST-503 as a potential therapy for chronic neuropathic pain, regardless of cause. Sangamo is preparing for the Phase 1/2 clinical study to assess the safety, tolerability and preliminary efficacy of a one-time dose of ST-503, administered intrathecally to patients with intractable pain due to iSFN, and plans to initiate patient enrollment in mid-2025. Sangamo believes that if this study is successful, the development of ST-503 could be broadened to patient populations suffering from other types of chronic neuropathic pain. Reported Earnings • Nov 14
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: US$0.051 (up from US$0.59 loss in 3Q 2023). Revenue: US$49.4m (up 426% from 3Q 2023). Net income: US$10.7m (up US$114.8m from 3Q 2023). Profit margin: 22% (up from net loss in 3Q 2023). The move to profitability was primarily driven by higher revenue. Revenue exceeded analyst estimates by 97%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings. New Risk • Nov 14
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.07% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$179m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings are forecast to decline by an average of 0.07% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$26m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding). Major Estimate Revision • Nov 07
Consensus revenue estimates fall by 17% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$41.2m to US$34.1m. Forecast losses increased from -US$0.53 to -US$0.554 per share. Biotechs industry in the US expected to see average net income decline 14% next year. Consensus price target up from US$3.80 to US$4.80. Share price rose 65% to US$2.81 over the past week. Aankondiging • Nov 05
Sangamo Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Sangamo Therapeutics, Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024 Major Estimate Revision • Aug 23
Consensus revenue estimates increase by 32% The consensus outlook for revenues in fiscal year 2024 has improved. 2024 revenue forecast increased from US$31.3m to US$41.2m. Forecast losses expected to reduce from -US$0.483 to -US$0.461 per share. Biotechs industry in the US expected to see average net income decline 14% next year. Consensus price target of US$3.80 unchanged from last update. Share price fell 2.5% to US$0.86 over the past week. Reported Earnings • Aug 07
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: US$0.18 loss per share (improved from US$0.66 loss in 2Q 2023). Revenue: US$356.0k (down 95% from 2Q 2023). Net loss: US$36.1m (loss narrowed 68% from 2Q 2023). Revenue missed analyst estimates by 96%. Earnings per share (EPS) also missed analyst estimates by 23%. Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings. Aankondiging • Jul 31
Sangamo Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Sangamo Therapeutics, Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024 New Risk • Jul 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$218m). Currently unprofitable and not forecast to become profitable over next 3 years (US$23m net loss in 3 years). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (US$83.3m market cap). Major Estimate Revision • May 21
Consensus EPS estimates fall by 10% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$42.8m to US$38.8m. Losses expected to increase from US$0.44 per share to US$0.48. Biotechs industry in the US expected to see average net income decline 11% next year. Consensus price target of US$3.50 unchanged from last update. Share price rose 5.2% to US$0.60 over the past week. New Risk • May 13
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$218m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$218m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Shareholders have been diluted in the past year (21% increase in shares outstanding). Reported Earnings • May 10
First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023) First quarter 2024 results: US$0.27 loss per share (down from US$0.13 profit in 1Q 2023). Revenue: US$481.0k (down 100% from 1Q 2023). Net loss: US$49.1m (down 332% from profit in 1Q 2023). Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Aankondiging • May 10
Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024 Sangamo Therapeutics, Inc. reported impairment charges for the first quarter ended March 31, 2024. For the quarter, the company reported impairment of long-lived assets of $4,349,000 compared to $20,433,000 a year ago. Aankondiging • May 03
Sangamo Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024 Sangamo Therapeutics, Inc. announced that they will report Q1, 2024 results After-Market on May 09, 2024 Aankondiging • May 01
Sangamo Therapeutics, Inc. Receives A Deficiency Notice from Nasdaq On April 24, 2024, Sangamo Therapeutics, Inc. (the Company") received a deficiency notice, or the Notice, from the Listing Qualifications Staff, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that, for the last 30 consecutive business days, the bid price of the Company's common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until October 21, 2024, or the Compliance Date, to regain compliance with the minimum bid price requirement by having shares of the Company's common stock maintain a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days before the Compliance Date. If the Company's common stock does not achieve compliance by the Compliance Date, the Company may be eligible for an additional 180-day period to regain compliance. To qualify for the second compliance period, the Company would be required to transfer its listing to the Nasdaq Capital Market and meet the continued listing requirement for market value of publicly held shares and all other applicable initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for the second compliance period, and the Company does not regain compliance by the Compliance Date, the Staff will provide written notification that the Company's common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set in the applicable Nasdaq listing rules. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by Nasdaq to the panel, such appeal would be successful. The Company intends to actively monitor the closing bid price of its common stock between now and the Compliance Date and, as appropriate, will evaluate available options to resolve the deficiency and regain compliance with the minimum bid price requirement. Aankondiging • Apr 21
Sangamo Therapeutics, Inc., Annual General Meeting, Jun 04, 2024 Sangamo Therapeutics, Inc., Annual General Meeting, Jun 04, 2024, at 08:30 Pacific Standard Time. Agenda: To elect the nine nominees for director named in the proxy statement, or the Proxy Statement, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified; to approve, on an advisory basis, the compensation of named executive officers, or NEOs; to approve the amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan, or the 2018 Plan, to, among other things, increase the aggregate number of shares of common stock reserved for issuance under the 2018 Plan by 11,000,000 shares; to ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2024; and to transact such other business as may properly come before the meeting. New Risk • Apr 19
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$98.8m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (25% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$88m net loss in 3 years). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (US$98.8m market cap). Aankondiging • Mar 25
Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24 million. Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 24,761,905
Price\Range: $0.84
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 3,809,523
Price\Range: $0.84
Transaction Features: Registered Direct Offering Aankondiging • Mar 22
Sangamo Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $24 million. Sangamo Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $24 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 24,761,905
Price\Range: $0.84
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 3,809,523
Price\Range: $0.84
Transaction Features: Registered Direct Offering Major Estimate Revision • Mar 20
Consensus revenue estimates fall by 13% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$42.5m to US$36.9m. Forecast losses increased from -US$0.483 to -US$0.499 per share. Biotechs industry in the US expected to see average net income decline 8.2% next year. Consensus price target of US$3.50 unchanged from last update. Share price fell 11% to US$0.77 over the past week. Aankondiging • Mar 14
Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023 Sangamo Therapeutics, Inc. reported impairment results for the fourth quarter ended December 31, 2023. For the quarter, the company reported Impairment of long-lived assets of $0.3 million. Reported Earnings • Mar 13
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: US$1.48 loss per share (further deteriorated from US$1.25 loss in FY 2022). Revenue: US$176.2m (up 58% from FY 2022). Net loss: US$257.8m (loss widened 34% from FY 2022). Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) also missed analyst estimates by 6.9%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings. 
